TikTok’s mental health ‘minefield’ may be unreliable or misleading: Study

Social media platforms have become a go-to source for mental health information, especially among young users. But a new study suggests that much of what people encounter online, particularly on TikTok, may be unreliable or even misleading.

Researchers from the University of East Anglia (UEA) found that a significant share of posts related to conditions such as ADHD and autism contain inaccuracies or lack proper evidence. Their analysis, which covered multiple platforms including YouTube, Facebook, Instagram and X, points to a broader issue: misinformation around mental health is widespread, and in some cases, alarmingly high.

The study reviewed more than 5,000 posts across a range of mental health topics, from anxiety and depression to schizophrenia and eating disorders. It found that misleading content could make up as much as 56 per cent of posts in certain areas, highlighting how easily unverified claims can spread in highly engaging formats like short videos.

Among all platforms, TikTok stood out for having the highest levels of questionable content. According to the researchers, over half of the ADHD-related videos analysed, and around 52 per cent were found to be inaccurate. For autism-related content, the figure stood at 41 per cent. By comparison, misinformation rates were lower on YouTube, averaging about 22 per cent, and even lower on Facebook at under 15 per cent.

Experts say this matters because social media is increasingly shaping how young people understand their mental health. Many turn to these platforms to interpret symptoms or self-diagnose conditions. While this can sometimes prompt useful self-reflection, it also carries risks when the information is incomplete or incorrect.

Misleading content can blur the line between normal behaviour and clinical conditions, potentially leading people to wrongly believe they have a disorder, or, conversely, delay seeking help when they actually need it. It may also reinforce stigma, create unnecessary fear, or promote treatments that lack scientific backing.

The study also highlights a stark divide between who is creating content and how reliable it is. Posts made by healthcare professionals were consistently more accurate, but they represent only a small fraction of what users see. For instance, just 3 per cent of ADHD-related videos by professionals contained misinformation, compared to 55 per cent among non-professional creators.

wikipedia.org/

At the same time, the researchers acknowledge that personal stories and lived experiences shared by individuals can play a valuable role in raising awareness and helping others feel understood. The challenge lies in ensuring that such content is complemented by clear, evidence-based guidance from qualified experts.

Another key factor driving misinformation is the way platforms like TikTok operate. Their algorithms tend to prioritise content that is engaging and widely shared, regardless of its accuracy. Once users show interest in a topic, they are often fed a steady stream of similar videos, creating echo chambers where misleading ideas can quickly gain traction.

There are, however, some exceptions. The study found that YouTube Kids performed notably better, with no misinformation detected in content related to anxiety and depression, and relatively low levels, and around 8.9 per cent for ADHD. Researchers attribute this to stricter moderation and content controls.

Overall, the findings point to a growing need for stronger safeguards. The authors call for better moderation systems, clearer standards for identifying misinformation, and more active participation from clinicians and health organisations in creating accessible, trustworthy content.

As social media continues to shape public understanding of mental health, the study makes one thing clear: while these platforms can be powerful tools for awareness, without reliable information, they can just as easily become a source of confusion.

Also Read:

Social media culture can encourage risky and inappropriate posting behavior

Mass media linked to childhood obesity

FDA Approves Bristol Myers Squibb’s New Antipsychotic Drug Cobenfy for Schizophrenia Treatment

The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride), for the treatment of schizophrenia, a chronic mental health disorder. Developed by Karuna Therapeutics and now owned by Bristol Myers Squibb, Cobenfy works by targeting cholinergic receptors unlike traditional antipsychotic medications that target dopamine receptors.

This marks a significant departure from the conventional approach to schizophrenia treatment, according to the FDA. Schizophrenia is a debilitating mental illness characterized by hallucinations, delusions, disorganized thinking, and behavioral disturbances. Those affected often struggle to maintain a grasp on reality and may experience cognitive impairments.

Globally, about 24 million people are living with schizophrenia, including 2.8 million in the U.S., where it ranks as one of the top 15 causes of disability. Tragically, the condition is linked to a shortened lifespan, with approximately 5% of patients dying by suicide, the FDA noted.

The approval of Cobenfy is seen as a hopeful development for individuals affected by schizophrenia. “Schizophrenia is a leading cause of disability worldwide. It is a severe, chronic mental illness that profoundly impacts quality of life,” said Tiffany Farchione, Director of the Division of Psychiatry at the FDA’s Center for Drug Evaluation and Research. “This drug offers the first new approach to treating schizophrenia in decades, providing an alternative to previously prescribed antipsychotic medications.”

The effectiveness of Cobenfy was demonstrated in two clinical studies. Over a five-week period, patients’ symptoms were measured using the Positive and Negative Syndrome Scale (PANSS), a 30-item tool used to assess schizophrenia symptoms. Results showed that patients treated with Cobenfy experienced a significant reduction in symptoms compared to those on a placebo.

However, the FDA highlighted several side effects associated with the drug, including nausea, constipation, vomiting, increased heart rate, and diarrhea. Due to the risk of severe side effects, the agency advised against prescribing Cobenfy to patients with urinary retention, kidney, or liver disease.

Earlier this year, in March, Bristol Myers Squibb acquired Karuna Therapeutics for $14 billion, gaining exclusive rights to KarXT (Cobenfy). The company plans to launch the drug by the end of October, with a monthly cost of $1,850, or around $22,500 annually, according to Reuters.

Sales are projected to reach $2.5 billion in the U.S. by 2030. Bristol aims to provide insurance coverage for 80% of patients within the first 12 to 18 months of the drug’s release. To further assist patients, Bristol has introduced a support program called “COBENFY Cares.”

Childhood trauma behind schizophrenia, hallucinations among elders, reveals study

Brain Image (NIH)

Researchers have shown that childhood sexual, physical and emotional abuse are associated with severe hallucinations in schizophrenia.

The joint study by several research institutes found that hallucinations in schizophrenia were linked with childhood trauma, said Sarah Bendall, the lead author.

The study has analyzed 29 studies on childhood trauma and psychotic symptoms and found that childhood sexual abuse is often associated with delusions, seen among patients with schizophrenia.

“This means there’s something about childhood trauma that leads some people to develop hallucinations,” Bendall said. The symptoms include unrealistic attitude, unemotional attitude, hallucinations, delusions, disorganised thinking, and lack of motivation.

The study was jointly conducted by Orygen, the National Centre of Excellence for Youth Mental Health; the University of Melbourne; Port Phillip Prison and University Hospital of Gran Canaria Dr Negrin, Spain.

Bendall said many patients fail to provide this evidence during the treatment, thus missing the key link. It was found that one in every 100 people will experience a psychotic disorder in their lives, majority of them facing it during 18-25 years.

“When young people come to youth mental health services, we should be assessing for trauma and for emerging psychotic symptoms, and treating them as soon as they emerge,” Dr Bendall said. “It’s a very empowering thing to be able to give people that information.”

The study was published in the journal Schizophrenia Bulletin.